Novaccess Global Inc. · OTC:XSNX
Novaccess Global — Investor Presentation (April 2022)
23 slides from Novaccess Global's investor presentation, April 2022
Slide 1: NovAccess Global
Confidential and Proprietary. Copyright 2022 by NovAccess Global, Inc. All Rights Reserved. Market Symbol XSNX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This information package contains forward-looking statements, which includes forecasts and timelines. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “will”, “proposes”, “expects”, “estimates”, “intends”, “anticipate
Slide 3: About Us
About Us IND stage biopharmaceutical company developing next‐generation immunotherapies to treat Brain Cancer An SEC-registered, OTC markets public company seeking FDA approval for a Phase IIa Human clinical trial An expert scientific and managerial team focused on bringing novel cancer therapeutics
Slide 4: Our Focused Mission
Our Focused Mission Acquisition of cutting-edge assets in oncology Enhance and accelerate bringing to market novel brain tumor Utilization of our expert advisory immunotherapies board to accelerate going to market Confidential 2022 Market Symbol XSNX
Slide 5: Dwain Irvin, Chief Executive Officer
Dwain Irvin, Chief Executive Officer Educational Background PhD, UCLA School of Medicine, Molecular & Medical Pharmacology, 2002 MPH, UCLA School of Public Health, Environmental Sciences, 1995 BA, The Johns Hopkins University, 1988 Asst. Professor, Research Scientist, Cedars-Sinai Medical Center, Ne
Slide 6: Dwain Irvin, Chief Executive Officer
Dwain Irvin, Chief Executive Officer Ventures Co-Founder of 2 start-up companies in Biotechnology and Stem Cell Biology. • CEO, NovAccess Global Inc. • Accelerating and Investing in cancer Therapeutics and Diagnostics • President, Biotech Division, Innovest Global Inc. 2018 – 2020 • Acquire biotech
Slide 7: Our Team
Our Team Each Contributor, an Expert in their Field – Highly Focused, yet Adaptable Management Dwain Irvin PhD, MPH Neil Laird Christopher Wheeler PHD Chief Executive Officer Chief Financial Officer President, StemVax Therapeutics Co-Founder T-Neuro Executive Board Scientific Advisory Board John Cas
Slide 8: Milestones
Milestones Q2 2022 Preparing to Up-List on OTC Markets (OTCQB) Q3 2021 FDA pre-IND interaction: FDA states that XSNX is not required to do additional pre-clinical R&D studies and provides a road map for an IND Phase IIa application submission Q3 2020 StemVax acquired by NovAccess Global, an active O
Slide 9: Glioblastoma
Glioblastoma • More than 21,000 brain tumors diagnoses were estimated for 2021 in the U.S. • Glioblastoma is the most common primary adult brain tumor • Five-year survival rates are less than 5% for GBM • Despite advances in Radiation and Chemotherapy no change in GBM patient survival in over 40 yea
Slide 10: Glioblastoma Market Analysis
Glioblastoma Market Analysis 2018, Global, $700 Million Market size, CAGR 9.3% (GlobalData Inc. 2019) 2026, US, 2.9 Billion Market Size (GlobalData Inc. 2019) No current immunotherapy for brain tumors Expect 5% market penetration within first 5 years in market Confidential 2022 Market Symbol XSNX
Slide 11: Glioblastoma: Problem and Solution
Glioblastoma Problem: • Standard of Care: Surgical resection followed by radiation and chemotherapy • 15-month median survival • No Cures, additional GBM therapies needed Solution: • Immunotherapy: 3 Major Types 1. Administration of antigen-pulsed dendritic cell (DC) immunotherapy 2. Cytokine-transf
Slide 12: Immunotherapy Against Glioblastoma
Immunotherapy Against Glioblastoma History of Technology Licensed from Cedars-Sinai Medical Center, Department of Neurosurgery Cedars-Sinai Medical Center ranked 8th in US; Neurosurgery Department ranked 12th in US (US World New and Reports, 2020) NovAccess Global technology is 3rd Generation immuno
Slide 13: Third Generation Immunotherapy
Immunotherapy Against Glioblastoma Third Generation Immunotherapy 3rd Generation 35% improvement over 1st generation in animals 1st and 2nd Generation Improves survival in GBM responders (Phase I, II) NOT a cure – Reduces chance of GBM recurrence Confidential 2022 Market Symbol XSNX
Slide 14: Brain Tumor Immunotherapy
Brain Tumor Immunotherapy Tumor Blood TUMOR ANTIGEN CELLS ANTIGEN-PRESENTING CELLS (Dendritic Immune Cells) Neurosurgeon Isolates Tumor and Immune Cells - Sends to Lab Confidential 2022 Market Symbol XSNX
Slide 15: Brain Tumor Immunotherapy
Brain Tumor Immunotherapy ANTIGEN-PRESENTING CELLS TUMOR ANTIGEN CELLS (Dendritic Immune Cells) Immune Cells Process Tumor Antigens Utilizing TLR-AD1 Technology Confidential 2022 Market Symbol XSNX
Slide 16: Brain Tumor Immunotherapy
Brain Tumor Immunotherapy Giloma Tumor Cell Lysate Freeze-Thaw Method Used to Activate Immune Response ‘Intelligence-Briefed’ Immune Cells Introduced into Bloodstream T-Cells Trained to Identify Tumor and Anti-Tumor Response Initiated TLR-AD1 Glioblastoma Vaccine Administered Confidential 2022 Marke
Slide 17: Dendritic Cell Vaccine (1st Generation)
Dendritic Cell Vaccine (1st Generation) Improves survival in responders (Phase I and II) Not a cure - Reduces chance of GBM recurrence Needs improvement-survival rates, outcomes Confidential 2022 Market Symbol XSNX
Slide 18: 1st Generation Vaccine-Bulk Tumor Lysate
1st Generation Vaccine-Bulk Tumor Lysate TTS (time from surgical resection immediately preceding vaccination to time of death) -Wheeler et al, 2008, Cancer Research Confidential 2022 Market Symbol XSNX
Slide 19: 2nd Generation Vaccine Common Antigens (ICT-107)
2nd Generation Vaccine 6 Common Antigens (ICT-107) ICT-107 - Targets Cancer Stem Cells Lead Indication in GBM Antigen Treats gp100 melanoma, brain MAGE-1 melanoma, brain, ovarian IL-13Ra2 brain, ovarian Her-2/neu breast, ovarian AIM-2 breast, colon, brain Trp-2 melanoma, brain Confidential 2022 Mark
Slide 20: 3rd Generation Vaccine
3rd Generation Vaccine 2nd Generation Vaccine Phase II data not encouraging Antigen specific or antigens derived from bulk lysate combined with Toll- like receptor (TLR) adjuvants Pre-clinical mouse model data show significant improvements in survival and dendritic cell activation and function Confi
Slide 21: 3rd Gen vs. 1st Gen
3rd Gen vs. 1st Gen Pre-Clinical (Animal Study) Kaplan-Mier Survival Analysis of Vaccinated Glioma Bearing Mice (Controls) Median Survival • 1st Gen: 60 days • 3rd Gen + TLR Combos: 81 days Confidential 2022 Market Symbol XSNX
Slide 22: Company Highlights
Company Highlights NovAccess Global, IND stage biopharmaceutical company developing next-generation immunotherapy products to treat Brain Cancer Applying to uplist in OTC Markets (OTC-QB), Q2, 2022 Filing Orphan Drug status in Q2, 2022 File Phase IIa IND application by Q4 2022 Confidential 2022 Mark
Slide 23: Thank You!
Thank You! Confidential 2022 Market Symbol XSNX
NovAccess Global — Investor Presentation (April 2022) on 6ix